在多发性骨髓瘤的临床与基础研究方面取得了一系列成果，先后在Blood Cancer Journal、Molecular Cancer Research等杂志发表第一/共一作者文章5篇，相关工作多次在国际骨髓瘤协会年会（IMS）和美国血液学年会(ASH)进行口头报告及壁报，两次获得IMS颁发的青年研究者奖。主持国自然青年科学基金一项，参与国自然科学基金重点项目以及医科院重大协同创新项目等重点课题。

(1) Tengteng Yu T ; Bharat Chaganty; Liang Lin; Lijie Xing; Boopathy Ramakrishnan; Kenneth Wen;Phillip A. Hsieh; Andrew Wollacott; Karthik Viswanathan; Hedy Adari; Shih-Feng Cho; Yuyin Li;Hailin Chen; Wenjuan Yang; Yan Xu; Gang An; Lugui Qiu; Nikhil Munshi; Gregory Babcock; Zachary Shriver; James R. Myette; Kenneth C. Anderson; Yu-Tzu Tai ; VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo, Blood Cancer Journal, 2020, 10(11): 1-13 .

(2) Tengteng Yu T ; Yan Xu; Gang An; Yu-Tzu Tai; Matthew Ho; Zengjun Li; Shuhui Deng; Dehui Zou;Zhen Yu; Mu Hao; Kenneth C. Anderson; Lugui Qiu ; Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China, Clinical Lymphoma Myeloma& Leukemia, 2020, 20(10): E652-E659 .

(3) Tengteng Yu T ; Chenxing Du; Xiaoke Ma; Weiwei Sui; Zhen Yu; Lanting Liu; Lei Zhao; Zhongqing Li; Jie Xu; Xiaojing Wei; Wen Zhou; Shuhui Deng; Dehui Zou; Gang An; Yu-Tzu Tai; GuidoTricot; Kenenth C. Anderson; Lugui Qiu; Fenghuang Zhan; Mu Hao ; Polycomb-like Protein 3 inducesproliferation and drug resistance in multiple myeloma and is regulated by miRNA-15a, Molecular Cancer Research, 2020, 18(7): 1063-1073.

(4) 于滕滕; 安刚; 徐燕; 邱录贵 ; 原发性浆细胞白血病的临床和生物学进展, 白血病淋巴瘤, 2018,27(7): 434-437 .

(5) 于滕滕 于 ; 安刚; 李承文; 徐燕; 邓书会; 隋伟薇; 郝牧; 邱录贵 ; 伴t(11;14)多发性骨髓瘤的临床研究, 白血病 淋巴瘤, 2017, 26(6): 325-329 .